FDA Panel to Review Amgen's Humira Biosimilar

Source: Zacks

Jun 14, 2016

Amgen announced that the FDA’s Arthritis Advisory Committee will be reviewing data supporting the company's biologics license application for ABP 501, the biosimilar version of AbbVie's top-seller, Humira.

A final decision reagarding approval from the FDA is expected September 25 of this year. Amgen currently has nine biosimilar candidates in its portfolio and is hoping to launch its first biosimilar in 2017 followed by four others through 2019.

AbbVie's Humira recorded worldwide sales of $14 billion in 2015 and, as of last year, was the best-selling branded drug in the United States.

Read the Zacks coverage

Show Comments
Hide Comments

Join the discussion

We welcome your thoughtful comments.
All comments will display your user name.

Want to participate in the discussion?

Register for free

Log in for complete access.


No one has commented on this page yet.

RSS feed for comments on this page | RSS feed for all comments